Longeveron (LGVN) Net Cash Flow (2020 - 2026)
Longeveron (LGVN) recorded quarterly Net Cash Flow of $11.1 million in Q1 2026, up 342.13% quarter-over-quarter from -$4.6 million in Q4 2025, and up 326.24% on a YoY basis from $2.6 million in Q1 2025.
Longeveron (LGVN) Net Cash Flow (2020 - 2026) Analysis & Trends
Longeveron's Net Cash Flow history runs 7 years deep, the most recent figure standing at $11.1 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 326.24% year-over-year to $11.1 million; the TTM figure through Mar 2026 stood at $1.4 million (down 88.45% YoY), while the FY2025 annual figure was -$14.6 million, down 202.02% from the prior year.
- Net Cash Flow was $11.1 million for Q1 2026 at Longeveron, up from -$4.6 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $11.1 million in Q1 2026 to a low of -$6.6 million in Q3 2022.
- Historically, Net Cash Flow has averaged -$582352.9 across 5 years, with a median of -$3.0 million in 2024.
- Biggest YoY gain for Net Cash Flow was 1433.72% in 2024; the steepest drop was 218.91% in 2024.
- A 5-year view of Net Cash Flow shows it stood at -$3.1 million in 2022, then jumped by 197.1% to $3.0 million in 2023, then slumped by 218.91% to -$3.5 million in 2024, then dropped by 29.24% to -$4.6 million in 2025, then soared by 342.13% to $11.1 million in 2026.
- The last three Net Cash Flow figures came in at $11.1 million (Q1 2026), -$4.6 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 664,983.53 |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 11.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.10 Mn |
| Mar 31, 2026 | 11.10 Mn |
| Dec 31, 2025 | -4.58 Mn |
| Dec 31, 2025 | -4.58 Mn |
| Sep 30, 2025 | -1.09 Mn |
| Sep 30, 2025 | -1.09 Mn |
| Jun 30, 2025 | -3.99 Mn |
| Jun 30, 2025 | -3.99 Mn |
| Mar 31, 2025 | -4.91 Mn |
| Mar 31, 2025 | -4.91 Mn |
| Dec 31, 2024 | -3.55 Mn |
| Dec 31, 2024 | -3.55 Mn |
| Sep 30, 2024 | 10.40 Mn |
| Sep 30, 2024 | 10.40 Mn |
| Jun 30, 2024 | 10.44 Mn |
| Jun 30, 2024 | 10.44 Mn |
| Mar 31, 2024 | -3.01 Mn |
| Mar 31, 2024 | -3.01 Mn |
| Dec 31, 2023 | 2.98 Mn |
| Dec 31, 2023 | 2.98 Mn |